QAS Tranexemic Acid DTP

Class

Anti-fibrinolytic

Pharmacology

A competitive inhibitor of plasminogen activation through the formation of a reversible complex displacing plasminogen for fibrin. This inhibits the process of fibrinolysis in addition to the protein breakdown caused by plasmin.

Metabolism:

Hepatic metabolism with renal excretion

Indications:

1. Recent traumatic injuries (3 hours or less) with a COAST score of 3 or greater

2. Management of uncontrolled primary post-partum haemorrhage (3 hours or less)

3. Management of post-tonsillectomy haemorrhage (evidence of active haemorrhage)

Contraindications

Allergy and/or adverse drug reaction

Precautions

Nil

Side effects

1. Headache

2. Hypotension

3. Nausea and/or vomiting

4. Seizures

Presentation

Ampoule: 1g/10ml

Onset

Minutes

Duration

Serum 7-8 hours

Half life

2 hours

Adult doses: all indications

IV: 1g slow push over 10 minutes, single dose only

IV infusion: 1g mixed with 100ml of NS infused over 10 minutes, single dose only

IO: 1g slow push over 10 minutes, single dose only

IO infusion: 1g over 10 minutes, prepared with 1g (10ml) in a 30ml Springfusor syringe using rate 60ml/hr (over 10 minutes)

Paediatric dose: recent traumatic injuries

IV and IO: 15mg/kg, slow push over 10 minutes, single dose only, total max dose 1g

Clinical consultantation required in all cases

Paediatric dose: post-tonsillectomy

IV and IO: 15mg/kg, slow push over 10 minutes, single dose only, total max dose 1g